News

Gladstone in the News January 5, 2022

Indoor Dining May Once Again Be Too Risky Due to Omicron, Bay Area Health Experts Warn

San Francisco Chronicle—Senior Investigator Warner Greene, MD, PhD, recommends that people limit indoor dining, especially if they are over 65 or otherwise at elevated risk for COVID-19, while the Omicron wave washes over the Bay Area.

Gladstone Experts COVID-19 Center for HIV Cure Research Infectious Disease Greene Lab

Gladstone in the News December 15, 2021

Blocking an Immune System Molecule in Mice May Help Prevent Long-Term Disabilities after Traumatic Brain Injury

The Conversation—Individuals who survive traumatic brain injury can suffer from life-long complications, such as cognitive deficits, seizures, and sleep disruption. Jeanne Paz, PhD, describes her work in mice showing that treatment with an antibody that blocks an element of immune system activation may be able to prevent such consequences.

Gladstone Experts Traumatic Brain Injury Neurological Disease Paz Lab

Gladstone in the News December 15, 2021

New COVID-19 Nasal Spray Therapy Aims to ‟Reduce Viral Load in the Lungs by 100-Fold”

abc7 NEWS—Senior Investigator Leor Weinberger, PhD, and Research Investigator Sonali Chaturvedi, PhD, explain their work on a therapy that sharply reduces viral load in the nose of hamsters after a single administration and could add a promising new tool to the therapeutic arsenal against COVID-19.

Gladstone Experts COVID-19 Infectious Disease Weinberger Lab

Gladstone in the News December 14, 2021

Virus-Hijacking COVID-19 Drug from Gladstone Researchers Slows Down Variants, Expects Clinical Trial Early Next Year

San Francisco Business Times—Senior Investigator Leor Weinberger, PhD, pioneered a new class of antivirals called therapeutic interfering particles (TIPs), which were recently shown to be effective against SARS-CoV-2 in animal models. The approach is now being developed by a startup company and will be headed to clinical trials.

Gladstone Experts COVID-19 Center for Cell Circuitry Infectious Disease Weinberger Lab

Gladstone in the News December 14, 2021

How Effective Are Today’s Vaccines against Omicron? Here’s What We Know So Far

San Francisco Chronicle—The omicron variant of SARS-CoV-2 is spreading rapidly, but it may not be a reason for panic. Nadia Roan explains that our immune system’s cellular response to the vaccines should hold up well against the omicron variant. In addition, Warner Greene predicts that if the variant spreads rapidly but causes just mild disease, it might actually help establish immunity globally, protecting people in places where vaccine access has been limited.

Gladstone Experts COVID-19 Greene Lab Roan Lab

Video December 10, 2021

What to Expect in 2022

Gladstone virologists discuss Omicron and what we might expect in 2022 from the COVID-19 pandemic

Gladstone Experts COVID-19 Greene Lab Ott Lab

Gladstone in the News December 8, 2021

How Severe Is Omicron? Expert Says Variant’s 50 Mutations Could Be Its Downfall

abc7 News—Senior Investigators Warner Greene, MD, PhD, and Nevan Krogan, PhD, discuss the possibility that Omicron, although more transmissible than previous SARS-CoV-2 variants, may cause less severe disease.

Gladstone Experts COVID-19 Center for HIV Cure Research Data Science and Biotechnology Infectious Disease Greene Lab Krogan Lab

Gladstone in the News December 6, 2021

Bay Area Scientists Rush to Study Local Omicron Virus Samples for Health Clues

San Francisco Chronicle—The identification of an individual infected with the Omicron variant of SARS-CoV-2 in San Francisco is helping local scientists assess the danger posed by the virus. Melanie Ott, director of the Gladstone Institute of Virology, explains that experiments using virus samples from that individual could help determine how well the available vaccines hold up to Omicron’s mutations.

Gladstone Experts COVID-19 Infectious Disease Ott Lab

Article December 1, 2021

How Close Are We to a Cure for HIV?

Researchers at Gladstone Institutes focus on innovative strategies that could finally allow people living with HIV to stop taking daily medications

Gladstone Experts HIV/AIDS Infectious Disease Greene Lab Ott Lab Roan Lab Weinberger Lab Deep Dive

Gladstone in the News December 1, 2021

TBI One Love Podcast

Brain Injury Radio—On a radio show dedicated to traumatic brain injury (TBI), Associate Investigator Jeanne Paz, PhD, explains her life-long interest and current work in TBI and in epilepsy, a common long-term consequence of brain damage.

Gladstone Experts Traumatic Brain Injury Epilepsy Paz Lab

Gladstone in the News December 1, 2021

Do COVID Vaccines Work against Omicron? What We Know So Far

San Francisco Chronicle—The emerging Omicron variant of SARS-CoV-2 features several mutations in its spike protein that in theory could make it resistant to current vaccines. But Associate Investigator Nadia Roan, PhD, explains that current vaccines will still protect against Omicron, as they elicit a variety of antibodies and immune T cells that target non-mutated areas of spike.

Gladstone Experts COVID-19 Infectious Disease Roan Lab

Gladstone in the News November 26, 2021

Experts Peg Omicron as “Worst Variant That We Have Come Across”; Here’s What They Know So Far

ABC News—A new variant of SARS-CoV-2, dubbed Omicron, is causing concern around the world. Gladstone President Deepak Srivastava explains that some of the variant’s 50 mutations may have arisen when an individual who was already immunocompromised became infected with the virus. Senior Investigator Nevan Krogan describes how his group is investigating whether the new mutations will change the ability of the virus to enter cells and cause disease.

Gladstone Experts COVID-19 Data Science and Biotechnology Infectious Disease Krogan Lab Srivastava Lab

Video November 18, 2021

Innovators of Genomic Immunology

Watch recordings from the Gladstone-UCSF Institute of Genomic Immunology Symposium

Gladstone Experts Genomic Immunology Marson Lab Pelka Lab Genomics

Gladstone in the News November 18, 2021

New Clues to Delta Variant’s Spread in Studies of Virus-Like Particles

NIH Director’s Blog—The Delta variant of SARS-CoV-2 is driving the latest surge of COVID-19 cases in the United States. New research from Senior Investigators Jennifer Doudna and Melanie Ott explains how mutations in this variant increase transmissibility.

Gladstone Experts COVID-19 Infectious Disease Doudna Lab Ott Lab

Gladstone in the News November 16, 2021

Unique Repurposing Approach Identifies Potential Alzheimer’s Disease Drug

BioIT World—Despite decades of research, medical therapies for Alzheimer’s disease have so far proven elusive. Senior Investigator Yadong Huang describes how his innovative approach to drug repurposing has identified a promising candidate drug that is now moving toward clinical trials.

Gladstone Experts Alzheimer’s Disease Neurological Disease Huang Lab